Introduction

D
espite advances in surgical technique and perioperative care, blood loss after elective joint arthroplasty remains an issue. Historical averages for the decrease in hemoglobin (Hb) after unilateral total knee arthroplasty and total hip arthroplasty are approximately 3 to 4 g/dL 1 because of a combined effect of blood loss and hemodilution. Greater blood loss may occur after bilateral or revision surgery.
Transfusion of blood products has long been the mainstay of postoperative anemia treatment. With other factors being equal, a higher hemoglobin level is beneficial postoperatively. However, the most effective means to obtain these levels must be examined. Allogeneic transfusions carry certain risks, such as disease transmission and reactions 2 , clerical error, and
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of increasing oxygen delivery with allogeneic transfusions. Transfusions also substantially increase the length of stay 4 , interfere with therapy, and deliver an inherently negative psychological impact and perception of illness. With fixed blood bank resources and administration costs 10, 11 , transfusions drive hospital admission costs 10% to 20% higher 12 .
Based on current practices, orthopaedists should reexamine the "10/30 rule" of 1942, which suggests transfusion for a hemoglobin level of ,10 g/dL and a hematocrit of ,30%
13 . Historical transfusion rates have been as high as 59% following revision total hip arthroplasty 14 . Blood management for patients undergoing hip and knee arthroplasty is defined by the goals of ensuring appropriate circulating volume and minimizing routes for blood loss. Avoiding allogeneic transfusion and its attendant risks is a byproduct of this philosophy.
Several key advances and a development in our understanding of blood management have shaped the way that we should view transfusions and practice variability 15 . The current review evaluates these techniques, pharmaceuticals, and tools. It is divided into strategies that are applicable in the preoperative, intraoperative, and postoperative periods. It should be noted that the associated end points of blood management strategies vary throughout the perioperative course. For example, while host optimization and adequate blood volume and hemoglobin concentration are important in the preoperative period, tools and techniques to limit blood loss gain importance in the intraoperative period. Ultimately, the goal of blood management strategies is to reduce morbidity and mortality following elective joint arthroplasty. A summary of trends and effectiveness of each strategy is found in Table I .
Preoperative Considerations Algorithms
The hemoglobin level can affect the quickness of recovery 16 , although most of the data used to support this premise are qualitative. Perioperative risks are associated with a lower preoperative hemoglobin level, especially in patients with a history of cardiac disease 17 . Baseline anemia is more prevalent with increasing age 18 . More than one-third of patients who are managed with arthroplasty have a baseline hemoglobin level of ,13 g/dL 14 , and a systematic review demonstrated anemia rates of 24% to 44% 19 . A strong predictor of transfusion has been a lower preoperative hemoglobin level, with ,13 g/dL being a common historical threshold 14 B l o o d M a n a g e m e n t f o r P a t i e n t s U n d e r g o i n g To t a l J o i n t A r t h r o p l a s t y | . In a clinical study of patients with hip fractures, no benefit in terms of mortality was seen in association with transfusion in patients with a hemoglobin level as low as 8 g/dL 5 .
Certainly, no optimum hemoglobin threshold exists for all patients; rather, the threshold is based on multiple factors 90 .
Acute Normovolemic Hemodilution
This technique involves collecting two to three autologous units immediately preoperatively or while the patient is under anesthesia 91 . Normovolemia is then maintained with crystalloids and/or colloids to effect a replacement of whole blood with acellular fluids. Acute normovolemic hemodilution may be considered when intraoperative blood loss is likely to exceed 20% of blood volume and the preoperative hemoglobin level is .10 g/dL 2 . This method has been reported to be efficacious in the setting of joint arthroplasty 92 and has been found to be as effective as preoperative autologous donation for reducing the risk of transfusion 93 . A metaanalysis of forty-two trials demonstrated a modest blood-conservation benefit, but only one-third of the reports included information on adverse events 94 .
Acute normovolemic hemodilution is less costly than preoperative autologous donation 95 , and a systematic review demonstrated it to be more cost effective than cell salvage 96 . Hemodilution should be used with caution in the
n a g e m e n t f o r Pa t i e n t s U n d e r g o i n g To t a l J o i n t A r t h r o p l a s t y
elderly, and it is generally contraindicated for patients with certain conditions such as anemia and coronary artery disease 60 .
Antifibrinolytic Medications
Antifibrinolytic medications have been used for more than five decades in various surgical disciplines, including dentistry and cardiac surgery 97 . Specific interventions, such as tourniquet and pneumatic compression stocking use, can accelerate fibrinolysis. Antifibrinolytic medications work along the fibrinolytic cascade to prevent the dissolution of established fibrin clots; they are not so-called procoagulant medications. Despite a traditional underusage of antifibrinolytic medications in orthopaedics, the utility and efficacy of these medications has gained recent interest. Tranexamic acid, a synthetic lysine analog, competitively saturates plasminogen binding sites. This inhibits the activation of plasminogen to plasmin and the subsequent breakdown of fibrin clot 98 . This drug has a short-term effect (a half-life of two hours), is rapidly excreted in the urine, and preferentially inhibits fibrinolysis in the surgical field as compared with the general circulation 99 . As of 2009, the U.S. Food and Drug Administration (FDA) indicated tranexamic acid (Cyklokapron; Pfizer, New York, NY) for the prevention of blood loss during tooth extraction in hemophiliacs 100 . Available in both intravenous and topical formulations, the cost is around $60 to $71 per gram in the United States and $6 per gram in Canada. The recommended dosing is 10 to 20 mg/kg per dose, and multiple doses are more effective than single bolus 101 .
Tranexamic acid remains the best studied of the antifibrinolytic medications in orthopaedic surgery. Early studies demonstrated lower blood loss 102 , including a dose-dependent effect 103 . Benefit was seen when tranexamic acid was combined with cell salvage in the setting of revision total hip arthroplasty 104 . Meta-analyses [105] [106] [107] have demonstrated less blood loss and fewer transfusions in the setting of total knee arthroplasty, with no increased thromboembolic risk. Meta-analyses of other types of arthroplasty have echoed these findings [108] [109] [110] .
While those studies showed promising results, caution must be taken when interpreting the meta-analysis data. The majority of studies presented short-term follow-up data, and techniques for the detection of venous thromboembolic events (deep venous thrombosis and pulmonary embolus) varied widely. The studies generally excluded high-risk patients, and, therefore, so-called proof-of-safety results may not be extrapolated to all patients. Scientific power is lacking for definitive support in high-risk patients. While tranexamic acid has shown efficacy, one may only state that it appears to be relatively safe for the majority of patients.
While the use of tranexamic acid has been associated with several minor and major side effects (e.g., nausea, diarrhea, and orthostatic reactions, with case reports of cerebral and arterial thrombosis and seizures) 98, 111 , there are no established contraindications. Contemporary orthopaedic dosing has been far lower than historical total or loading schemes used in cardiac surgery 112 .
Therefore, the avoidance of tranexamic acid use for certain patients-such as those with recent stents or strong history of venous thromboembolic diseaseremains more practice-based at this time. Epsilon-aminocaproic acid, another lysine analog, is six to ten times less potent than tranexamic acid and therefore is used in a different dosing regimen. Like tranexamic acid, it has a short halflife (one to two hours) and is renally excreted. At $0.56 to $1.12 per patient, epsilon-aminocaproic acid (Amicar; Xanodyne Pharmaceuticals, Newport, Kentucky) is less expensive than tranexamic acid 113 . This agent has shown utility in scoliosis surgery 114 .
Aprotinin is a serine protease inhibitor. First-generation animal products have been supplanted by second-generation recombinant human sources. While reduced blood loss and transfusion rates have been shown in some studies on total knee arthroplasty and total hip arthroplasty, the benefits have been unclear in other reports 122, 123 . The demonstrated benefits have been limited by studies involving small 124 or industry-linked cohorts.
With uncertain benefits, the issue of cost must be weighed carefully. A Cochrane Review suggested that fibrin products are associated with benefits in terms of blood loss but cautioned against the general lack of study blinding 125 .
Other Medications
Desmopressin, a synthetic analog of vasopressin, increases the levels of factor VIII and von Willebrand factor. It has been shown to reduce total blood loss in the setting of total hip arthroplasty 126 , while other studies have shown no benefit 127 . Recombinant factor VIIa, which enhances thrombin formation on activated platelets, is FDA-approved for the management of hemophiliac bleeding 128 . Its use should be reserved for unique circumstances (e.g., 139, 140 . A metaanalysis showed benefits across multiple types of surgery, including total hip arthroplasty 141 .
Cell Salvage
Cell-salvage machines may provide the equivalent of ten banked blood units per hour 2 . The more immediately available salvaged blood may have a higher oxygen-carrying capacity and erythrocyte viability than preoperatively donated autologous blood 142 . In early studies, cell salvage reduced transfusion rates up to 60% 143 , which was borne out in a later meta-analysis 144 . Salvage has shown utility in the setting of revision total hip arthroplasty 145 , especially in patients with preoperative anemia and/ or low body weight 146 .
Because of hemolysis, only 60% of salvaged blood is returned 147 . Erythrocyte viability is maintained despite processing, even when exposed to bone cementation 148 . Cell salvage is generally used during arthroplasty only when expected blood loss exceeds 1000 mL 80 because at least two units must be recovered for the method to be clinically effective and cost-effective 2 . Salvage has limited utility in routine primary arthroplasty 149 . It cannot be used in the setting of tumor or infection 150 . There are limited data on the revision of metalon-metal bearings 151 . Cochrane Reviews by the same authors in 2006 and 2010 demonstrated that salvage was associated with a transfusion benefit, despite the poor quality of the included trials 152, 153 . While those reports represent recent comprehensive reviews, they may not encompass the results seen in association with more contemporary collection systems.
Tourniquet
Tourniquet use increases fibrinolytic activity. Controversy exists with regard to the effect on blood loss. In 2011, a meta-analysis of eleven studies demonstrated that tourniquet use did not decrease calculated blood loss 154 . In 2010, a meta-analysis of fifteen studies demonstrated higher intraoperative blood loss without tourniquet use but showed no difference in terms of total blood loss or transfusions 155 . In 2012, a meta-analysis demonstrated a decrease in total and intraoperative blood loss in association with tourniquet use 156 .
Operative Technique
Atraumatic dissection and meticulous hemostasis play a role. Minimizing the time that bleeding surfaces are exposed can slow blood loss, and the average blood loss is less for surgeons with higher volume and shorter operative times 157 .
Lower blood loss has been reported in association with lateral total hip arthroplasty positioning as a result of the effects of gravity in reducing venous engorgement 158 . A rapid and watertight closure enhances the tamponade effect over the surgical bed 159 .
The use of extramedullary instrumentation for total knee arthroplasty and plugging of the canals with autologous bone or cement during total knee arthroplasty with instrumentation may be employed. Some studies have demonstrated higher transfusion rates in association with cementless total hip arthroplasty and total knee arthroplasty 160 . With improved understanding of component rotation and patellar tracking, the use of lateral release for total knee arthroplasty may be minimized. There is conflicting evidence to support the advantage of minimally invasive methods with regard to blood loss, and early experience with certain approaches has demonstrated more transfusions and increased operative times 161 . Clearly, variations in technique and other intraoperative factors may confound studies examining the effects on blood loss.
Use of Drains
Controversy exists regarding the effect of drains on blood loss. A meta-analysis of studies on total hip arthroplasty and total knee arthroplasty demonstrated greater risk of transfusion in association with drain usage (relative risk, 1.43) 162 . Likewise, a meta-analysis of studies on total knee arthroplasty demonstrated that closed suction drainage increased the rate of transfusion 163 .
Pooled data from six controlled trials demonstrated no clear advantage in terms of the transfusion rate in association with drain clamping postoperatively 164 , although the studies did not control for the effects of intravenous volume expansion and red blood-cell dilution.
Postoperative Management Prudent Transfusion Triggers
The evaluation of the patient undergoing total joint arthroplasty for blood transfusion must be based on the individual scenario, operative course, and comorbidities. Indeed, most postoperative clinical symptoms traditionally attributed to "anemia" are related to volume rather than to a problem with oxygen delivery. These volume deficits are often addressed appropriately with crystalloid fluid first. While intravascular volume repletion may lead to an effective hemodilution, adequate tissue oxygen extraction from circulating red blood cells may be maintained because of an unchanged red blood-cell mass. Reports in the anesthesia literature have indicated that even highrisk patients with low hemoglobin levels have preservation of metabolic function when sufficient intravascular volume is present 165 . Goal-directed therapy following total hip arthroplasty with the patient under regional anesthesia has demonstrated a reduction in complications without transfusion differences 166 .
Despite a National Institutes of Health (NIH) Consensus Statement 167 in the 1980s recommending a decrease in the hemoglobin transfusion threshold from 10 to 8 g/dL for patients with no history of cardiac disease, the practice of transfusions for patients with a hemoglobin level of around 10 g/dL still continues. A restrictive transfusion threshold (hemoglobin level, 7 g/dL) has shown no difference in comparison with a liberal transfusion threshold (hemoglobin level, 10 g/dL) in terms of overall mortality in critical care patients 168 .
More stringent criteria have been endorsed in other surgical fields 169, 170 .
The American Society of Anesthesiologists has recommended transfusion for patients with a hemoglobin level of ,6 g/dL and generally not for those with a hemoglobin level of .10 g/dL 171 .
Guidelines from the American Association of Blood Banks outline a restrictive strategy (a threshold hemoglobin level of 7 to 8 g/dL) for hospitalized, stable patients 172 . Cardiac disease, symptoms, or a hemoglobin level of #8 g/dL may prompt transfusion. Two controlled trials demonstrated no benefit in terms of the use of transfusion in association with a threshold hemoglobin level of .8 g/dL, even in patients with comorbid cardiac disease 173, 174 .
Reinfusion Drains
Available since the 1980s, reinfusion drains were found to be efficacious with respect to transfusions in early 175 and later 176 studies. Other studies have contradicted this utility 177 . A metaanalysis of eight randomized studies of total knee arthroplasty showed benefits in terms of the length of stay and the transfusion rate in association with the use of reinfusion drains as compared with suction drains 178 . Filtration and washing reduces transfusion reactions but increases cost 179 . Because of cost and the quantity of blood required for processing, perhaps the best role for reinfusion drains lies in bilateral or revision arthroplasty.
Conclusions
Blood management in joint arthroplasty is defined by the goals of ensuring appropriate circulating volume and minimizing sources of blood loss. Avoiding allogeneic transfusion and its associated risks are a closely related aim. Careful analysis of transfusion risks must be performed preoperatively. A multimodal approach must be adopted at all time points in the surgical pathway. Blood management guidelines must be tailored to the individual patient 180 .
Evaluation of safety is critical, especially when combining treatment modalities. The effectiveness of many techniques remains to be proved on the basis of large-scale trials or pooled study data with sufficient power for certain conclusions or rare events. Multicenter study groups also may effect a reduction in practice variability and costs 181 .
Broadening indications to higher-risk groups also will define safety and efficacy, including those of antifibrinolytic medications. Cost metrics must be closely considered with respect to emerging technology. For primary total hip arthroplasty and total knee arthroplasty, and for the majority of revision procedures, one must change one's thinking; specifically, preferential crystalloid volume support, in conjunction with modern blood conservation strategies, should precede the administration of blood cell products. This philosophy, along with a multimodal strategy including antifibrinolytic therapy, should consistently reduce the need for allogeneic transfusions.
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